Riskpilot← Back to searchSign inGet full accessUute Scientific Oy
OYActiveY-tunnus 2988085-7Haartmaninkatu 4Other manufacturing n.e.c. · NACE 3299Est. 2019— employeeswww.uutescientific.com
Revenue 2024
EUR 205K
+121% vs 2023
EBITDA margin
410.1%
-21% vs 2023
Equity ratio
-178.8%
Financial strength
Net profit 2024
EUR -515K
-25% vs 2023
| Revenue | EUR 205K | +121% |
| EBITDA | EUR 839K | -21% |
| Net profit | EUR -515K | -25% |
| Total assets | EUR 592K | +28% |
| Equity | EUR -1,1M | -95% |
| Employees | — | — |
Legal name
Uute Scientific Oy
Y-tunnus number
2988085-7
Legal form
Osakeyhtiö
NACE code
3299 · Other manufacturing n.e.c.
Founded
8. maaliskuuta 2019
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Immunomodulaaristen tuotteiden valmistaminen, valmistuttaminen, lisensointi, markkinointi, konsultointi ja tutkimus sekä kaikki muu laillinen liiketoiminta.
Address
Haartmaninkatu 4
Phone
+358503860444
Email
kari.sinivuori@uutescientific.com
Website
www.uutescientific.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 80 | 115 | 93 | 205 |
| Staff expenses | −110 | −144 | 391 | 404 | 398 |
| EBITDA | −114 | −238 | 989 | 1 062 | 839 |
| Depreciation & amort. | −3 | −32 | 48 | 48 | 48 |
| EBIT | −117 | −270 | −805 | −344 | −418 |
| Net financials | 0 | −6 | −97 | — | — |
| Profit before tax | −117 | −276 | −903 | −412 | −515 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −117 | −276 | −903 | −412 | −515 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 410 | 460 | 836 | 464 | 592 |
| Equity | 335 | 58 | −132 | −543 | −1 058 |
| Long-term debt | — | 279 | 845 | 825 | 1 546 |
| Short-term debt | 76 | 124 | 123 | 182 | 104 |
| Total debt | 76 | 402 | 968 | 1 007 | 1 650 |
EBITDA margin
410.1%
This company
15.8%
Market median
+2496% vs market
20202024
Equity ratio
-178.8%
This company
38.2%
Market median
-568% vs market
20202024
Return on equity
-51486100.0%
This company
18.4%
Market median
-279815861% vs market
20202024
Net profit margin
-251.7%
This company
8.1%
Market median
-3207% vs market
20202024
Asset turnover
0.35×
This company
1.12×
Market median
-69% vs market
20202024
Debt / equity
1.56×
This company
0.62×
Market median
-152% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-09-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2019-03-01 – 2020-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KU Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
JT Audit | Audit | 2020 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Former (1) | ||
| Board of Directors | 2019 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Uute Scientific Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jussi Tapio Paski | Audit | 0 companies |
| Kari Urpo Sinivuori | Chief Executive Officer | 0 companies |
| Aki Tapio Sinkkonen | Board of Directors | 0 companies |
| Oliver Jörg Norbert Boldt | Board of Directors | 0 companies |
| Olli Heikki Laitinen | Board of Directors | 0 companies |
| Heikki Antero Hyöty | Board of Directors | 0 companies |